BAY 85-8501

Drug Profile

BAY 85-8501

Alternative Names: BAY 858501

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer HealthCare
  • Class Bronchodilators
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bronchiectasis

Most Recent Events

  • 03 Sep 2016 Adverse events data from a phase II trial in Bronchiectasis presented at the 26th Annual Congress of the European Respiratory Society 2016 (ERS-2016)
  • 30 Jun 2014 Bayer completes a phase IIa trial in Bronchiectasis in United Kingdom, Spain, France, Germany & Italy (NCT01818544)
  • 08 Mar 2013 Phase-II clinical trials in Bronchiectasis in France, Germany & Italy (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top